Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex
June 02, 2022 09:00 ET
|
Qualigen Therapeutics, Inc.
Transaction expected to significantly advance commercial readiness of NanoSynex’s innovative diagnostics technology platform focused on the $30+ Billion global infectious disease testing market ...
Qualigen Therapeutics’ Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting
May 26, 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
Abstracts Highlight In Vitro and In Vivo Activity of Qualigen’s Pan-RAS inhibitor in (1) Pancreatic Cancer, and (2) Malignant Peripheral Nerve Sheath Tumors CARLSBAD, Calif., May 26, 2022 (GLOBE...
Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation on RAS Program
March 15, 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics CEO Michael Poirier Provides Letter to Shareholders
February 22, 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial Results
August 17, 2021 08:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif.,, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announces its intention to prioritize its focus to its oncology pipeline that includes QN-247...